First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2014-11-03 11:26:24Open Document File Size: 31,46 KBShare Result on FacebookCityOsaka / /CompanyShionogi & Co. Ltd. / Amylin Pharmaceuticals Inc. / Corporate Communications Department Shionogi & Co. Ltd. / /CountryJapan / United States / /FacilityKyoto University Hospital / Translational Research Center / University Graduate School / / /IndustryTermforeign healthcare reforms / with respect to product / /MedicalConditionleptin deficiency / Lipodystrophy Lipodystrophy / insulin resistance / Lipodystrophy / disease / severe insulin resistance / diabetes / hyperlipidemia / severe diabetes / rare and life-threatening disorder / Intractable Diseases / hypertriglyceridemia and fatty liver disease / /OrganizationKyoto University Graduate School / Department of Medicine and Clinical Science / Kyoto University Hospital / Translational Research Center / Ministry of Health / /PersonIsao Teshirogi / / /PositionPresident & CEO / /PublishedMediumClinical Science / /TechnologyDrug Discovery / /SocialTag |